Fiser Richard T, West Nancy K, Bush Andrew J, Sillos Elaine M, Schmidt Jeffrey E, Tamburro Robert F
Pediatric Critical Care and Cardiology, University of Arkansas for Medical Sciences College of Medicine, Little Rock, AR 72202-3591, USA.
Pediatr Crit Care Med. 2005 Sep;6(5):531-6. doi: 10.1097/01.pcc.0000165560.90814.59.
To describe survival to intensive care unit (ICU) discharge and 6-month survival in a large cohort of pediatric oncology patients with severe sepsis.
Retrospective analysis.
The ICU of a single pediatric oncology center.
Patients with cancer admitted to the ICU of St. Jude Children's Research Hospital between January 1, 1990, and December 31, 2002, who met the following criteria: 1) severe sepsis by ACCP/SCCM (American College of Chest Physicians/Society of Critical Care Medicine) Consensus Conference criteria and 2) receipt of fluid boluses of > or =30 mL/kg to correct hypoperfusion or receipt of a dopamine infusion of >5 microg.kg.min for inotropic support.
None.
Data evaluated were demographic variables, oncologic diagnosis and time from diagnosis to ICU admission, Pediatric Risk of Mortality III score and absolute neutrophil count at admission, use of inotropes or pressors, use of mechanical ventilation, maximum organ system failure score, blood culture results, survival to ICU discharge, and 6-month survival. We identified 446 ICU admissions of 359 eligible patients. Overall ICU mortality was 76 of 446 (17%): 40 of 132 (30%) in post-bone marrow transplant (BMT) admissions and 36 of 314 (12%) in non-BMT admissions (p < .0001). In the 106 admissions requiring both mechanical ventilation and inotropic support, ICU mortality was 68 of 106 (64%). Regarding individual patients, 6-month survival was 170 of 248 (69%) among non-BMT patients vs. 43 of 111 (39%) for BMT patients (p < .001). When the 38 patients who survived to ICU discharge after requiring both mechanical ventilation and inotropic/vasopressor support are considered, 27 (71%) were alive 6 months after ICU discharge (22 of 27 [81%] non-BMT vs. 5 of 27 BMT [19%; p < .001]). ICU mortality varied by causative pathogen, from 63% for fungal sepsis (12 of 19) to 9% (5 of 53) for Gram-negative sepsis. Logistic regression analysis of factors significantly associated with ICU mortality in admissions requiring both mechanical ventilation and inotropic support identified four variables: BMT (odds ratio, 2.9; 95% confidence interval, 1.1-7.4; p = .03); fungal sepsis (odds ratio, 10.7; 95% confidence interval, 1.2-94.4; p = .03); use of multiple inotropes (odds ratio, 4.1; 95% confidence interval, 1.4-11.8; p = .01); and Pediatric Risk of Mortality III score (odds ratio, 1.1; 95% confidence interval, 1.0-1.2; p = .04).
In a large series of pediatric oncology patients with severe sepsis, ICU mortality was only 17% overall, although mortality remained quite high in the higher acuity patients. Mortality among the higher acuity patients was significantly associated with only a small number of variables. The number of patients alive at 6 months and the encouraging ICU survival rate further justifies the use of aggressive ICU interventions in this population.
描述一大群患有严重脓毒症的儿科肿瘤患者重症监护病房(ICU)出院生存率及6个月生存率。
回顾性分析。
单一儿科肿瘤中心的ICU。
1990年1月1日至2002年12月31日期间入住圣裘德儿童研究医院ICU的癌症患者,符合以下标准:1)根据美国胸科医师学会/危重病医学会(ACCP/SCCM)共识会议标准诊断为严重脓毒症;2)接受≥30 mL/kg的液体冲击以纠正低灌注,或接受多巴胺输注>5 μg·kg⁻¹·min进行血管活性药物支持。
无。
评估的数据包括人口统计学变量、肿瘤诊断及从诊断到入住ICU的时间、入院时的儿科死亡风险III评分及绝对中性粒细胞计数、血管活性药物或升压药的使用情况、机械通气的使用情况、最大器官系统功能衰竭评分、血培养结果、ICU出院生存率及6个月生存率。我们确定了359例符合条件患者的446次ICU入院情况。总体ICU死亡率为446例中的76例(17%):骨髓移植(BMT)后入院的132例中有40例(30%),非BMT入院的314例中有36例(12%)(p <.0001)。在106例既需要机械通气又需要血管活性药物支持的入院患者中,ICU死亡率为106例中的68例(64%)。就个体患者而言,非BMT患者的6个月生存率为248例中的170例(69%),而BMT患者为111例中的43例(39%)(p <.001)。当考虑38例在需要机械通气及血管活性药物/升压药支持后存活至ICU出院的患者时,27例(71%)在ICU出院后6个月仍存活(27例中的22例[81%]为非BMT患者,27例中的5例[19%]为BMT患者;p <.001)。ICU死亡率因致病病原体而异,真菌性脓毒症为63%(19例中的12例),革兰阴性菌脓毒症为9%(53例中的5例)。对既需要机械通气又需要血管活性药物支持的入院患者中与ICU死亡率显著相关的因素进行逻辑回归分析,确定了四个变量:BMT(比值比,2.9;95%置信区间,1.1 - 7.4;p =.03);真菌性脓毒症(比值比,10.7;95%置信区间,1.2 - 94.4;p =.03);使用多种血管活性药物(比值比,4.1;95%置信区间,1.4 - 11.8;p =.01);以及儿科死亡风险III评分(比值比,1.1;95%置信区间,1.0 - 1.2;p =.04)。
在一大系列患有严重脓毒症的儿科肿瘤患者中,总体ICU死亡率仅为17%,尽管病情较重患者的死亡率仍然很高。病情较重患者的死亡率仅与少数变量显著相关。6个月存活患者数量及令人鼓舞的ICU生存率进一步证明了对该人群积极采用ICU干预措施的合理性。